Presidio Ospedaliero Santa Maria delle Grazie — Clinical Trial Site

8 Registered trials

6 Currently recruiting

Organisation

Presidio Ospedaliero Santa Maria delle Grazie

Location

Località la Schiana, Pozzuoli (NA), Italy

Identifier

ORL-000000021

Address

Via domitiana, 80078, Italy

Departments

Medical Oncology Unit
Oncologia
Oncologia Medica
Oncology Department
U.O.C. Oncologia

Clinical trials at this site (8)

Search interface

Regorafenib as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, phase 2 study - STREAM-2 Recruiting

2024-519669-23-00 Patients with metastatic colorectal cancer (mCRC) RAS-m 4 2025-09-29
Randomized phase 2 study of Valproic acid combinEd with rechallenge anti-EGFR based regimen regimens in pretreated patients with RAS/BRAF wi… Recruiting

2024-514420-16-00 RAS/BRAF wild-type metastatic colorectal cancer 4 2024-12-18
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left … Recruiting

2023-509551-14-00 Unresectable left sided RAS/B-RAF wild-type metastatic 5 2024-06-12
Phase II study of axitinib intensification plus standard of care (SOC) compared to SOC alone after induction with nivolumab plus ipilimumab … Recruiting

2024-511397-70-00 metastatic renal cell carcinoma (mRCC) 4 2024-05-06
Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally adva… Recruiting

2024-513372-18-00 Pre- and post-menopausal women with HR+/HER2- LABC or M 4 2019-10-18
CETUXIMAB, IRINOTECAN AND FLUOROURACILE IN FIRST-LINE TREATMENT OF IMMUNOLOGICALLY-SELECTED ADVANCED COLORECTAL CANCER PATIENTS - the CIFRA … Recruiting

2024-518987-11-00 ADCC 4 2019-06-12
REVOLUTION - Randomized phasE 2 study of Valproic acid in combination with bevacizumab and Oxaliplatin/fLUoropyrimidine regimens in patients… Ended

2024-516844-25-01 Patients with ras-mutated metastatIc colorectal cancer 4 2019-01-03
Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended

2022-500785-10-00 Metastatic Castration-Resistant Prostate Cancer 5 2019-08-23